Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sellas Life Sciences Group Inc. (SLS:NASDAQ), powered by AI.
Sellas Life Sciences Group Inc. is currently trading at $7.83. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Sellas Life Sciences Group Inc. on Alpha Lenz.
Sellas Life Sciences Group Inc.'s P/E ratio is -31.8.
“Sellas Life Sciences Group Inc. trades at a P/E of -31.8 (undervalued) with modest ROE of -66.9%.”
Ask for details →Sellas Life Sciences Group Inc. is a biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapies. Its chief aim is to address unmet medical needs in oncology by advancing its proprietary platform of innovative targeted treatments. The company's core offerings include proprietary therapies designed to enhance the body’s immune response against various forms of cancer. Sellas is particularly notable for its research into therapies targeting hard-to-treat cancers such as acute myeloid leukemia and ovarian cancer. As it operates in the high-stakes biopharmaceutical sector, Sellas Life Sciences significantly impacts the healthcare industry by pushing the boundaries of possible cancer treatments. By collaborating with research institutions and leveraging cutting-edge technology, Sellas plays a pivotal role in the growing field of precision medicine, advancing treatment options that offer new hope to patients worldwide.
“Sellas Life Sciences Group Inc. trades at a P/E of -31.8 (undervalued) with modest ROE of -66.9%.”
Ask for details →Sellas Life Sciences Group Inc. (ticker: SLS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 15 employees. Market cap is $854M.
The current price is $7.83 with a P/E ratio of -31.79x and P/B of 12.05x.
ROE is -66.88%.